Showing results (41-50 of 126) with videos related to

Sort By:
Pageof 13
Blood Cancer Journal|October 6, 2018
Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working GroupLia A Moulopoulos, Vassilis Koutoulidis, Jens Hillengass, et al.
The New England Journal of Medicine|November 23, 2007
Lenalidomide plus dexamethasone for relapsed or refractory multiple myelomaMeletios Dimopoulos, Andrew Spencer, Michael Attal, et al.
Blood Cancer Journal|November 25, 2018
Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research ProjectSaad Z Usmani, Antje Hoering, Michele Cavo, et al.
Hematological Oncology|July 6, 2022
Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplantCirino Botta, Emilia Gigliotta, Bruno Paiva, et al.
Seminars in Hematology|May 12, 2023
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteriaSteven P Treon, Alessandra Tedeschi, Jesus San-Miguel, et al.
Blood|July 5, 2019
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myelomaSaad Z Usmani, Hareth Nahi, Maria-Victoria Mateos, et al.
The Lancet. Oncology|February 13, 2022
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 studyPaul G Richardson, Aurore Perrot, Jesus San-Miguel, et al.
Leukemia|September 8, 2020
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapseMeletios Dimopoulos, Katja Weisel, Philippe Moreau, et al.
British Journal of Haematology|April 6, 2021
Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trialTorben Plesner, Meletios A Dimopoulos, Albert Oriol, et al.
Haematologica|February 1, 2024
Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysisPaul G Richardson, Aurore Perrot, Jesus San Miguel, et al.
Pageof 13